BGB-11417-303
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Study ID
BGB-11417-303
ClinicalTrials.gov ID
EudraCT or EUCT Number
2024-517131-52-00
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
No Study Documents
Locations
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
No Study Documents